NCT01077908 - Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions

Cytomegalovirus Infection

Interventions

BIOLOGICAL

Adoptive Cellular Therapy

CMV-specific T-cells, single infusion at 27 days post-HSCT

DRUG

Best available antiviral drug therapy

"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"

Trial Locations (14)

Birmingham Heartlands Hospital, Birmingham

Queen Elizabeth Hospital, Birmingham

Beatson West of Scotland Cancer Centre, Glasgow

Royal Liverpool Hospital, Liverpool

Kings College Hospital, London

Royal Free Hospital, London

Christie Hospital, Manchester

Manchester Royal Infirmary, Manchester

City Hospital, Nottingham

Southampton General Hospital, Southampton

St James's University Hospital, Leeds

Bristol Royal Hospital for Children, Bristol

Addenbrookes Hospital, Cambridge

University College Hospital, London